David L Goode
Overview
Explore the profile of David L Goode including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
2170
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trigos A, Bongiovanni F, Zhang Y, Zethoven M, Tothill R, Pearson R, et al.
Genome Biol
. 2024 Apr;
25(1):110.
PMID: 38685127
Background: Metazoans inherited genes from unicellular ancestors that perform essential biological processes such as cell division, metabolism, and protein translation. Multicellularity requires careful control and coordination of these unicellular genes...
2.
Choo N, Keerthikumar S, Ramm S, Ashikari D, Teng L, Niranjan B, et al.
J Pathol
. 2024 Apr;
263(2):242-256.
PMID: 38578195
There are diverse phenotypes of castration-resistant prostate cancer, including neuroendocrine disease, that vary in their sensitivity to drug treatment. The efficacy of BET and CBP/p300 inhibitors in prostate cancer is...
3.
Brennen W, Le Magnen C, Karkampouna S, Anselmino N, Bock N, Choo N, et al.
Prostate
. 2024 Mar;
84(7):623-635.
PMID: 38450798
Background: There are relatively few widely used models of prostate cancer compared to other common malignancies. This impedes translational prostate cancer research because the range of models does not reflect...
4.
Chan L, Wang P, Abuhammad S, Lim L, Cursons J, Sheppard K, et al.
PLoS One
. 2023 Nov;
18(11):e0292278.
PMID: 37917641
Drugs targeting cyclin-dependent kinases 4 and 6 (CDK4/6) are promising new treatments for melanoma and other solid malignancies. In studies on CDK4/6 inhibitor resistance, protein arginine methyltransferase 5 (PRMT5) regulation...
5.
Feng Y, Yang T, Zhu J, Li M, Doyle M, Ozcoban V, et al.
Nat Commun
. 2023 May;
14(1):2697.
PMID: 37188662
Spatial proteomics technologies have revealed an underappreciated link between the location of cells in tissue microenvironments and the underlying biology and clinical features, but there is significant lag in the...
6.
Lawrence M, Taylor R, Cuffe G, Ang L, Clark A, Goode D, et al.
Nat Rev Urol
. 2023 Jan;
20(6):371-384.
PMID: 36650259
Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice. Serially transplantable PDXs are used to study tumour biology and test therapeutics, linking the laboratory to the clinic. Although...
7.
Risbridger G, Clark A, Porter L, Toivanen R, Bakshi A, Lister N, et al.
Nat Commun
. 2021 Aug;
12(1):5049.
PMID: 34413304
Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and systematic evaluation of...
8.
Lawrence M, Porter L, Choo N, Pook D, Grummet J, Pezaro C, et al.
Mol Cancer Ther
. 2021 Aug;
20(11):2140-2150.
PMID: 34413130
Monotherapy with PARP inhibitors is effective for the subset of castrate-resistant prostate cancer (CRPC) with defects in homologous recombination (HR) DNA repair. New treatments are required for the remaining tumors,...
9.
Teng L, Pereira B, Keerthikumar S, Huang C, Niranjan B, Lee S, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33799802
Mast cells (MCs) are important cellular components of the tumor microenvironment and are significantly associated with poor patient outcomes in prostate cancer and other solid cancers. The promotion of tumor...
10.
Porter L, Bakshi A, Pook D, Clark A, Clouston D, Kourambas J, et al.
J Pathol
. 2021 Feb;
254(2):121-134.
PMID: 33620092
Amplifications of the androgen receptor (AR) occur in up to 80% of men with castration-resistant prostate cancer (CRPC). Recent studies highlighted that these amplifications not only span the AR gene...